KEYMED BIO-B

Forecast & Rating16 analysts currently cover KEYMED BIO-B, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is HK$106.59, about 68.3% upside from the current price of HK$63.35. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 72.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study KEYMED BIO-B closely still see room for the stock to rise. Data as of Oct 27, 2026; for reference only and not investment advice.